Loading clinical trials...
Loading clinical trials...
A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor
Conditions
Interventions
Tafasitamab
Idelalisib
+1 more
Locations
17
United States
Clinical Study Site
Jacksonville, Florida, United States
Clinical Study Site
Rochester, Minnesota, United States
Clinical Study Site
Columbus, Ohio, United States
Clinical Study Site
Graz, Austria
Clinical Study Site
Salzburg, Austria
Clinical Study Site
Vienna, Austria
Start Date
November 1, 2016
Primary Completion Date
November 1, 2018
Completion Date
December 1, 2021
Last Updated
December 20, 2021
NCT06846671
NCT07218341
NCT06548152
NCT07030400
NCT07277231
NCT05006716
Lead Sponsor
MorphoSys AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions